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The aim of this work was to perform solubility studies for fexofenadine hydrochloride and establish 
dissolution conditions for this drug in oral suspension dosage form. The solubility study was executed 
through the shake-flask method, below 37 ºC±1 ºC, at 100 rpm stirring for 12 h in three buffer 
solutions: hydrochloric acid pH 2.0, acetate pH 4.5 and phosphate pH 6.8. The dissolution test was 
developed in vessels containing 900 mL of the same buffer, employing the paddle apparatus in speed 
of 25 and 50 rpm, below 37 ºC±0.5 ºC. The drug was classified as low solubility according to the 
Biopharmaceutics Classification System, since the dose/solubility ratio was higher than 250 mL in all 
media tested (326.55 mL in buffer pH 2.0; 2,456.33 mL in buffer pH 4.5 and 1,021.16 mL in buffer pH 
6.8). The dissolution test showed that a release of 85% in 30 min could be established. The rotation 
speed of 25 rpm, media volume of 900 mL and insertion of the samples through weighted syringes are 
adequate. The buffered media pH 2.0 could be chosen as dissolution media. 
Keywords: Fexofenadine hydrochloride. HPLC method. Biopharmaceutics. Suspension. Dissolution 
profile.
INTRODUCTION
Fexofenadine hydrochloride (FEX HCl) (Figure 1) 
is an inverse agonist of peripheral histaminic receptors 
H-1 (Simons, Simons, . It shows systemic distribution, 
but it does not cross the blood-brain barrier, and 
therefore does not induce sedation (Fromm, 2004). It 
is a zwitterion produced as racemic mixture (Aventis, 
2006). 
FIGURE 1 - Chemical structure of fexofenadine.
The drug has low aqueous solubility (Brasil 2010) 
which allows its manufacturing as an oral suspension. 
This dosage form is characterized for having two phases 
where the insoluble solid phase is dispersed in the liquid 
phase. When the objective is the quality control of the 
drugs administered in insoluble forms, the dissolution 
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study is requested (Brasil, 2011). Notwithstanding there 
are few recommendations of oral suspension dissolution 
procedures in the official compendia (Brasil, 2010; United 
States, 2013). In spite of having low solubility, it was 
recently shown that FEX HCl can be formulated as an 
orally disintegrated tablet for pediatric use. In this dosage 
form the dissolution was considered very fast (Türkmen, 
Ay Şenyiğit, Baloğlu, 2018). On, the other hand the drug 
dissolution is an auxiliary tool in the Biopharmaceutics 
Classification System, which evaluates the drug according 
its solubility and permeability (Amidon et al., 1995) 
and suggests one of the four classes: I – high solubility/
permeability, II – low solubility/high permeability, III – 
high solubility/low permeability and IV – low solubility/
permeability. The dissolution study is applied to verify 
the interference of excipients in drug release (Amidon 
et al., 1995). 
Although there are publications that develop 
dissolution methods for tablets and capsules comparing 
the performance of different apparatus, stirring rate, 
volumes and constitution of media (Breier et al., 2005; 
Oliveira, Weich, Rolim, 2007), one of our aims was to 
understand challenges in developing dissolution methods 
for oral suspensions dosage form. The second aim was 
to apply BCS approach to dissolution profile in vitro 
conditions that make it possible to preview differences 
in drug dissolution in vivo. Our contribution is to discuss 
relevant aspects that must be evaluated when testing 
suspensions. FEX HCl here was our model drug for its 
low solubility. Since the focus of this work is the study of 
the suspension oral liquid dosage form, studies about solid 
oral dosage forms, such as capsules and tablets, which are 
already well established, will not be discussed here.
This paper aims to highlight the biopharmaceutical 
characteristic of solubility for FEX HCl and develop a 
dissolution test for the oral suspension. This is essential 
information for the prediction of drug behavior in 
vivo, for monitoring product quality as well as for the 
development of generic medicines. This is an innovative 
work in this field considering the absence of similar 
experiments with FEX HCl. 
MATERIAL AND METHODS
Material
FEX HCl active pharmaceutical ingredient 
(CHIZOU, China) was purchased in Brazilian market, 
the Brazilian Pharmacopea standard reference substance 
was kindly provided by FIOCRUZ and the oral pediatric 
suspension (Allegra Pediátrico®, Sanofi Aventis, Brazil) 
was acquired in the local market. Acetonitrile (Merck-
LiChrosoh®, Germany) and methanol (JT Baker, Mexico) 
were purchased with chromatographic purity. Ultrapure 
water obtained from the DirectQ (Millipore, USA) was 
used. For the chromatographic analysis a C18 Zorbax 
Eclipse®, 150x4.6 mm, 5 µm column (Agilent, USA) and a 
high performance liquid chromatography with diode array 
detector 2695 (Waters, Milliford, USA) were employed. 
The solubility study was performed in the Shaker 
incubator KS 40000i Control (IKA, Germany). The oral 
suspension was characterized employing the rotational 
viscometer (Viscotester, ThermoScientific, USA) and 
Zetasizer PN 3072 (England). The dissolution test was 
developed in automatic dissolutor Vision® G2 Elite 8/
AutoPlus & Autofill (Hanson, USA).
Chromatographic Method
The mobile phase was constituted by monobasic 
phosphate buffer (pH 6.8, 25 mM) – acetonitrile (68:32, 
v/v). The buffer pH was adjusted with NaOH (1.0 M) 
before adding it to the organic solvent. The mobile phase 
was filtered in a 0.45 µm membrane and degassed for 
30 min in ultrasonic bath. Other established conditions 
were flow rate of 1.0 mL.min-1, temperature 30 ºC, 20 µL 
injection and detection at 220 nm.
The validation occurred according parameters 
established in the ICH Guidelines, in three media: pH 2.0 
hydrochloric acid buffer, pH 4.5 acetate buffer and pH 6.8 
phosphate buffer (United States, 2013). The analytical 
curves in the pH 2.0 and pH 4.5 buffers were obtained in 
the concentrations 15, 25, 40, 55, 70, 90 and 110 µg.mL-1 
and in the interval 15, 25, 40, 55, 70 and 90 µg.mL-1 in the 
pH 6.8 buffer. The curve solutions were prepared from 
the dilution of the fresh stock standard solution whose 
concentration was 500 µg.mL-1 in methanol. The method 
was validated according to linearity, precision, accuracy, 
robustness, quantification and detection limits. Selectivity 
was performed in triplicate using acid, alkaline and 
thermal stress conditions. The solutions were prepared at 
concentrations of 70 µg.mL-1 (ICH, 1996). 
Stability and Solubility Studies
The stability study employed triplicates of FEX HCl 
solutions at 55 µg.mL-1 in each buffer (n=9) which were 
prepared from the 525 µg.mL-1 stock standard solution 
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in methanol. The solutions were incubated in the same 
conditions established for the solubility measurement. 
Samples of 1 mL were collected after 1, 3, 6, 9 and 
12 h, filtered in 0.45 µm membrane before analyzed by 
HPLC. The FEX and possible degradation peaks were 
checked. Stability was evaluated by the relative standard 
deviation of concentrations for each time.
The solubility of FEX HCl (active pharmaceutical 
ingredient) was evaluated in triplicate using the 
following media (100 mL): pH 2.0 hydrochloric acid 
solution, pH 4.5 acetate and pH 6.8 phosphate buffers. 
The amounts of drug were 66mg of FEX HCl in pH 2.0, 
8mg in pH 4.5 and 16mg in pH 6.8.The test conditions 
were at temperature of 37 ºC±1 ºC, 100 rpm stirring for 
12 h with sample collection and medium replacement (1 
mL) at 1, 3, 5, 7, 9 and 12 h. The samples collected from 
pH 2.0 and pH 6.8 buffers were filtered and afterwards 
diluted 1:10 and 1:4, respectively in the same medium.
Oral Suspension Characterization
The oral suspension was characterized according 
to pH, viscosity, polydispersity index, particle size and 
zeta potential measurements. Viscosity and pH were 
determined in 100 mL of the shaken oral suspension 
placed into a beaker. A single drop of the suspension 
dispersed in 1 mL of ultrapure water was employed 
for the other determinations of particles size and zeta 
potential using Zetasizer PN3702 equipment. 
The FEX HCl content was determined by adding 
the oral suspension (5 mL) and methanol (100 mL) to a 
250 mL volumetric flask (n=3) followed by sonication 
for 30 min to promote extraction. Then, the flask 
volumes were completed with hydrochloric acid buffer 
pH 2.0 and sonicated for more 30 min. The solutions 
were passed through paper filter and 5 mL of the filtered 
sample were transferred to a 10 mL volumetric flask, 
whose volume was completed with the same buffer. 
These samples were filtered in 0.45 µm membrane 
before being quantified by HPLC.
In Brazil there is only a single product marked as 
oral suspension for FEX HCl.
Dissolution Study
Determination of Sink Condition
The sink condition was determined in each buffer. 
The dose of oral suspension used in the dissolution 
test (30 mg) was divided by the solubility in respective 
medium and the result was multiplied by 3. This volume 
was defined as the minimum necessary to maintain sink 
conditions to the dose.
Dissolution Test
The dissolution test was performed using paddle 
apparatus at 25 rpm and 50 rpm in pH 2.0, 4.5 and 
6.8 buffers maintained at 37 ºC±0.5 ºC until 45 min. 
Between 45 min and 60 min, the paddle rotation was 
established at 150 rpm. The 900 mL medium volume 
was defined in order to assure the sink conditions. 
The samples were inserted using glass syringes which 
were weighted when empty, filled and unfilled with 
the suspension. The aliquot withdrawal occurred 
with medium replacement (5 mL) at 2, 6, 10, 15, 30, 
45 and 60 min. The aliquots were filtered in 0.45 




The method was adequate to the purpose of 
solubility and dissolution studies of FEX HCl, showing 
selectivity, linearity, precision and accuracy according 
to the ICH guidelines. Figure 2 shows the method 
selectivity after 24 hours (96 ºC) for thermal stress, 
and 1 h for alkaline and acid stresses. The peak purity 
indicated the main peak was free of interferences, since 
the purity angle is smaller than the threshold angle. 
The method was linear in the range from 15 to 
110 µg.mL-1 to FEX solutions diluted in the pH 2.0 and 
4.5 buffers, and from 15 to 90 µg.mL-1 to FEX solutions 
diluted in the buffer pH 6.8 with correlation coefficient 
(R) values higher than 0.99 (Table I) Quantification and 
detection limits (Table I) were calculated (ICH, 1996). 
On the other hand the R2 indicates that the linearity 
data have high correlation, since it is the coefficient of 
determination (Kenneth, 2001). The relative standard 
deviation was lower than 5% for the lower, middle and 
higher concentrations, as requested in the law (ICH 
1996).The accuracy was observed when the method 
was used to quantify a substance of known purity, the 
fexofenadine hydrochloride reference substance. The 
values ranged from 98 to 103%, and that is considered 
adequate for accuracy in pharmaceutical products, where 
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the values may be placed between 95 and 105% (Rozet et 
al., 2007). This method was also precise in quantifying 
fexofenadine hydrochloride in low, intermediate and 
higher concentrations, as the RSD was lower than 5% 
(Table II).
The method was robust in most of conditions 
tested, except when changing the temperature to 29 ºC 
(RSD 2.36%) and the mobile phase proportion to 70:30 
(phosphate buffer: acetonitrile)(RSD 2.18%), which 
affected the results when FEX HCl is diluted in the pH 
6.8 phosphate buffer. The variability for other media 
used was not higher than 2% (Table III). 
FIGURE 2 - Chromatographic specter after acid stress of FEX HCl. A, b and c are the triplicates. D shows the substance was pure.
TABLE I - Chromatogram of FEX HCl after acid stress and dilution in (a) pH 2, (b) pH 4.5 and (c) pH 6.8 buffers; (d) FEX HCl 
UV purity spectrum’
Data pH 2.0 pH 4.5 pH 6.8
R2 0.999 0.997 0.999
R 0.999 0.999 0.999
Intercept -86459 -120735 -31583
Curve RSD 1.82 3.29 2.14
p-value** 0.28 0.44 0.70
Detection 3.83 1.55 1.79
Quantification 12.77 5.16 5.93
**If p-value is higher than 0.05, the intercept is not different from zero and data are homogenous. 
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TABLE II - Results obtained for precision and accuracy during method validation













TABLE III - Robustness of the validated chromatographic method






































Stability and Solubility Studies
The stability study performed showed that FEX 
HCl is stable in all three media used, since variations in 
concentrations in 12 h were so low that the results would 
not be affected by the time of analysis (Table IV). 
Solubility is defined in the calculation of dose/
solubility ratio, which should be lower than 250 mL 
to indicate high solubility of a drug. The dose can be 
defined as the highest commercial strength available 
(FDA, 2015) or as the highest dose orally (EMA, 
2010). The dose (D) employed was 30mg, the highest 
dose for the suspension. The solubility data, however, 
was the highest value achieved in the test, obtained 
after the establishment of the balance between the two 
phases in suspension, the aqueous buffer and the drug 
particles. The solubility value used is the one where 
the highest concentration is found until the equilibrium 
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is established and the values were measured as 551.21 
µg.mL-1 (pH 2.0), 73.28 µg.mL-1 (pH 4.5) and 176.27 
µg.mL-1 (pH 6.8). The study shows that FEX HCl is a 
low solubility drug (Figure 3), since the results for D/S 
were 326.55 mL in pH 2.0, 2,456.33 mL in pH 4.5 and 
1,021.16 in pH 6.8. Considering the maximum dose, 
which is 30 mg for FEX HCl in oral suspension, the 
results change to 54.42 mL, 409.39 mL and 170.19 mL in 
pH 2.0, 4.5 and 6.8, respectively, which characterizes the 
drug as having pH-dependent solubility. These buffers 
were chosen because they mimic the physiological pH in 
the gastrointestinal tract, and are recommended by the 
regulatory agencies (EMA, 2010; FDA, 2015).
TABLE IV - Relative standard deviation of concentrations 
of FEX HCl solutions evaluated in stability for each buffer 
between triplicates
%RSD FEX HCl  
Time 
(h)
pH 2.0 pH 4.5 pH 6.8
0 1.51 1.98 3.37
1 1.37 1.43 2.85
3 0.87 0.66 3.71
6 1.30 1.53 2.19
9 1.68 0.73 2.18
12 0.97 1.14 1.98
FIGURE 3 - Chromatogram of FEX HCl after alkaline stress and dilution in (a) pH 2, (b) pH 4.5, (c) pH 6.8 buffers and (d) FEX 
HCl UV purity spectrum.’
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Dissolution Study
The oral suspension purchased at the local market 
presented a pH 6.25 and viscosity of 135 mPa. The average 
size of the dispersed particles was 795.10 nm (n=3,%RSD 
1.66), the polydispersity index was 0.36 (n=3,%RSD 
4.6) and zeta potential was -36.70 mV (n=3,%RSD 2.4). 
These results indicate that the suspension has particles 
homogeneously distributed in size, has low viscosity 
comparatively to other medicines as suspension dosage 
form and is highly stable. The physical-chemical studies 
of suspensions show that smaller particles will exhibit 
a better profile in solubility and dissolution studies. 
Nanosized, micronized particles have facilitated diffusion 
in the solvent. Reducing particle sizes is a very practical 
method to increase the solubility of poor soluble drugs 
(Gowthamarajan, Singh, 2010).
A zeta potential different from the interval 
ranging ±30 mV suggests high stability, and values 
of polydispersity index close to zero demonstrate low 
variability in particle size. Both reflect stability and 
are related to the probability of sedimentation for 
the suspension, since the larger particles precipitate 
faster and the increase in zeta potential leads to 
higher repulsion between particles which cause their 
precipitation (Carstensen, Stremming, Pothisiri, 1972). 
The evaluation of the raw powder was not fulfilled. 
The excipients found in the oral suspension were 
propylene glycol, disodium edetate, propylparaben, 
diethylparaben, xantham gum, poloxamer, titanium 
dioxyde, monobasic sodium phosphate, dibase sodium 
phosphate, sucrose and xylitol. The oral suspension 
content was measured using the buffer pH 2.0 as 
diluent due to the higher solubility in this solution. 
In the absence of official monography for FEX HCl 
oral suspension, the limit value established was from 
90.0 to 110.0%, value cited in Brazilian pharmacopeia 
for fexofenadine hydrochloride tablets, and the results 
were 108.5%, 107.3% and 106.3% for each replicate. 
The use of buffered media in the physiological pH 
range representing portions of the TGI is important 
in proposing the in vitro conditions that enable better 
predictability of the in vivo behavior of the drug (FDA, 
2015). Sink condition was calculated for each buffer 
solution and it defines the volume of media needed to 
dissolve (3 times) the dose of the dosage form utilized. 
Results were 175.58 mL, 1,228.16 mL and 510.58 mL 
for pH 2.0, 4.5 and 6.8 buffers respectively. In face of 
that, the sink condition is not accomplished for buffer 
pH 4.5 since the dissolution should be performed in 
900 mL vessels. 
In the dissolution test the sample insertion 
method had huge effects on the conditions tested and 
the rotation speed of 25 rpm (Figure 4) generated 
 
FIGURE 4 - Chromatogram of FEX HCl after thermic stress and dilution in (a) pH 2, (b) pH 4.5, (c) pH 6.8 buffers and (d) FEX 
HCl UV purity spectrum.’
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more consistent profiles. This finding was observed 
in another work (Soares, 2016) developed in our 
laboratory, which tested variation in the insertion 
method through unloading the syringe in the central 
point or border of the vessels, and weighting or not the 
syringe. In that work smaller variation of dissolution 
results were found when inserting the sample by 
weighing the syringe before and after. Based on this 
previous observation, the difficulty was mentioned, 
but not tested in this study. There were discrepancies 
in the quantities dissolved in each time between the 
vessels and it was an impediment to calculate the 
dissolution efficiency for all the conditions, since some 
reached 85% release before 30 min. When the rotation 
speed of 50 rpm was used (Figure 5) the dissolution 
was considered very fast, 85% of the drug dissolved 
within 15 min. This is probably due to the particles of 
small size composing the oral suspension, which also 
showed great homogeneity. Under these conditions the 
procedure makes the test less discriminatory. Table V 
presents statistical data for the dissolution test in both 
rotation speeds and for the different pH solutions used. 
It shows that the variability between the vessels are 
enormous, although the process becomes homogeneous 
before 30 min of dissolution. 
It was observed that in the pH 6.8 buffer, the 
dissolution did not achieve 85% within 30 min in all 
vessels, thus it is not a good condition (Figures 3 and 
4). For the other buffers, a fast dissolution was verified, 
85% of the drug dissolved within 30 min. Nevertheless, 
the sink conditions are not reached in pH 4.5. From these 
results, the pH 2.0 buffer seems to be adequate for the 
dissolution test. The dissolution test, when developed 
to quality control, must be robust and discriminative 
in order to identify batches with problems. Different 
media, with distinct pH and variable rotation speeds 
are recommended (Limberg, Potthast, 2013). However 
it is also of great importance to know the drug solubility 
in each medium and the drug dosage form must be 
considered (Graffner, 2006). 
This method could be applied to routine of 
quality control and for biopharmaceutical purposes. 
In this field, it was noticed that rate of drug release 
does not represent a limit step for drug absorption. 
This fact is related to the smaller sizes of the particles, 
which improve the solubility speed by the media in 
FIGURE 5 - Equilibrium solubility curves of FEX HCl (n=3) in different buffers using shake flask method.
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vivo or in vitro. Among the excipients found in the 
oral suspension, it is known that poloxamer and 
propylene glycol increase the dissolution rate (Sruti 
et al., 2013). For quality control purposes simple 
aqueous buffers are appropriated, but when it is 
desirable to predict the drug in vivo behavior, buffers 
mimicking the physiological conditions that occur in 
the gastrointestinal tract are preferred. These solutions 
usually have the pH ranging from 1.2 to 6.8 (Limberg, 
Potthast, 2013), representing the environment in the 
stomach and the small intestine (Avdeef, 2003) and 
allowing to define if the dissolution from the dosage 
form is a limiting step for the drug absorption or 
if the formulation has impact in the drug release 
(Dressman et al., 1998). At this point, the dissolution 
is an important step in the biopharmaceutical studies, 
where solubility and permeability are also factors 
limiting the absorption of an active pharmaceutical 
ingredient (Amidon et al., 1995). 
Finally, the pH 2.0 buffer offered the best dissolution 
conditions when paddle apparatus at 25 rpm was used. 
The criterion is suggested based in release of 85% within 
30 min for FEX HCl in oral suspension 
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TABLE V - Statistical analysis of the dissolution test in pH 2.0, 4.5 and 6.8 using paddle apparatus rotation  speed of 25 and 50 rpm
Time 
(min)
FEX HCl % release (%RSD)
25 RPM 50 RPM
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